CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration.


Journal

Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521

Informations de publication

Date de publication:
15 Aug 2019
Historique:
received: 17 04 2019
revised: 31 05 2019
accepted: 05 06 2019
pubmed: 10 6 2019
medline: 21 9 2019
entrez: 10 6 2019
Statut: ppublish

Résumé

CD155 is a ligand of the NK activating receptor DNAM-1, it has been described in a variety of human malignancies, but its expression in breast cancer remains unclear and poorly studied. CD155 expression and NK cells infiltration were investigated in 158 patients with breast cancer by immunohistochemistry (IHC). Statistical analyses were performed to evaluate correlations of CD155 expression with clinical-pathological features, prognosis and tumor immunity. Tumor cytoplasmic CD155 (cyt-CD155) was associated with lymphovascular invasion (p = 0.011), and membranous CD155 (m-CD155) was strongly correlated with the presence of Tumor Infiltrating natural killer cells (NK-TILs) (p = 0.0003). Survival analysis demonstrated that patients with high cyt-CD155 had a significantly worse overall survival (p < 0.001) and death free survival (p = 0.014) than those with low expression, while high levels of m-CD155 correlated with a better prognosis (p = 0.037). Furthermore, we found that patients with m-CD155 Altogether, our results revealed that cyt-CD155 was associated with invasiveness and poorer prognosis, but the concomitant presence of m-CD155 and NK-TILs had an opposite prognostic relevance in breast cancer. These results raised the importance of CD155 IHC analysis to elucidate biomarker localization, leading to better understand and design therapeutic molecule targeting CD155 in breast tumors.

Identifiants

pubmed: 31176775
pii: S0024-3205(19)30463-1
doi: 10.1016/j.lfs.2019.116543
pii:
doi:

Substances chimiques

Antigens, Differentiation, T-Lymphocyte 0
CD226 antigen 0
Membrane Proteins 0
Receptors, Virus 0
poliovirus receptor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116543

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Hana Triki (H)

Laboratory of Molecular and Cellular Screening Processes, Centre de Biotechnologie de Sfax, Sfax, Tunisia.

Slim Charfi (S)

Department of Pathology, University Hospital Habib Bourguiba, Sfax, Tunisia.

Lobna Bouzidi (L)

Department of Pathology, University Hospital Habib Bourguiba, Sfax, Tunisia.

Wala Ben Kridis (W)

Department of Medical Oncology, University Hospital Habib Bourguiba, Sfax, Tunisia.

Jamel Daoud (J)

Department of Radiotherapy, University Hospital Habib Bourguiba, Sfax, Tunisia.

Kais Chaabane (K)

Department of Gynecology, University Hospital Hédi Chaker, Sfax, Tunisia.

Tahia Sellami-Boudawara (T)

Department of Pathology, University Hospital Habib Bourguiba, Sfax, Tunisia.

Ahmed Rebai (A)

Laboratory of Molecular and Cellular Screening Processes, Centre de Biotechnologie de Sfax, Sfax, Tunisia.

Boutheina Cherif (B)

Laboratory of Molecular and Cellular Screening Processes, Centre de Biotechnologie de Sfax, Sfax, Tunisia. Electronic address: boutheina.cherif.cbs@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH